分享到朋友圈
15
17
33
1137
0
淋巴瘤指南更新要点
外周T/NK细胞淋巴瘤及霍奇金淋巴瘤指南更新要点（NK/T, PTCL, HL）
专家评述
Real-world treatment patterns and clinical outcomes of patients with hodgkin lymphoma in east asia: final results from a b-holistic subgroup
淋巴瘤，如何更好实现保驾护航
2022 CSCO淋巴瘤诊疗指南
原发纵隔大B细胞淋巴瘤治疗关键节点
评BTK抑制剂BGB-3111在中国B淋巴细胞肿瘤患者中安全性耐受性以及药代药效动力学特征的I期临床研究 讲者：宋玉琴
Ibrutinib + Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Untreated Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma: a Chinese Subgroup Analysis of the Phase 3 PHOENIX Trial
Ibrutinib + Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients With Untreated Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma (DLBCL): a Chinese Subgroup Analysis of the Phase 3 PHOENIX Trial
全人源PD-1单抗GLS-010（赛帕利单抗）在中国复发或难治性经典型霍奇金淋巴瘤患者中的应用——一项多中心、单臂、关键二期临床研究试验结果
Current Standard Practice after ASCO 2019: Lymphoma
国家卫健委淋巴瘤专科化建设项目——临床学科发展的几点建议
ID 8005 KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) ID 8008 Interim analysis of ZUMA-5: A phase II study of axic
赛帕利单抗在淋巴瘤中的临床应用
立足中国，长期生存 ——倍诺达中国RELIANCE研究长期生存数据解读
专家点评
